By Tapan Panchal

LONDON--AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration had lifted its partial ban on head and neck cancer treatment drug trials, and the company had consequently resumed new patient enrolment for the trials.

The pharmaceutical company said the regulator lifted its partial hold on the enrolment of new patients with head and neck squamous cell carcinoma for clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

November 22, 2016 02:38 ET (07:38 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Astrazeneca Charts.